FDA approves first postpartum depression oral pill zuranolone

By Gabrielle M. Etzel

Published August 4, 2023 11:11pm ET

Add Washington Examiner on Google

FDA approves first postpartum depression oral pill zuranolone — The Food and Drug Administration has approved zuranolone, brand name Zurzuvae, the first-ever pill treatment for postpartum depression, or PPD. “Postpartum depression is a serious and potentially life-threatening condition in which women experience sadness, guilt, worthlessness—even, in severe cases, thoughts of harming themselves or their child,” said Tiffany R. Farchione, the FDA’s director of the […]

The Food and Drug Administration has approved zuranolone, brand name Zurzuvae, the first-ever pill treatment for postpartum depression, or PPD.

Print subscriber? Click here to login/register your account

Digital subscriber? Click here to login/register your account.

Full midterm coverage.Deeper analysis.

Get unlimited access to Washington Examiner's reporting, expert analysis, and coverage of the midterm elections.

Get Unlimited Access

Cancel anytime.

Tag:

Child Care Family FDA Pharmaceutical Industry Pregnancy Washington D.C. Women